U.S. FDA issues two observations to Dr. Reddy’s API plant in Telangana 


The United States Food and Drug Administration (U.S. FDA) has issued a Form 483 with two observations to generic drugmaker Dr. Reddy’s Laboratories’ active pharmaceutical ingredients (API) manufacturing facility in Miryalaguda, Telangana.

The U.S. FDA conducted a Good Manufacturing Practices (GMP) inspection of the API manufacturing facility (CTO-5) in Miryalaguda from May 19-24. “We have been issued a Form 483 with 2 observations, which we will address within the stipulated timeline,” the company said in a filing on Saturday.

  • Related Posts

    Lupin, China’s SUP ink pact for COPD drug Tiotropium DPI

    Lupin has signed a license and supply agreement with Sino Universal Pharmaceuticals (SUP) for commercialisation of chronic obstructive pulmonary disease drug Tiotropium Dry Powder Inhaler, 18 mcg/capsule, in the Chinese…

    Continue reading
    India to export 150 locomotives to Africa worth over ₹3,000 crore

    “These locomotives are fitted with Distributed Power Wireless Control System, or DPWCS, for synchronised operations and superior freight handling,” a Railways Ministry spokesperson said. Photo: https://www.wabteccorp.com/ India will supply 150…

    Continue reading

    Leave a Reply

    Your email address will not be published. Required fields are marked *